Literature DB >> 28462602

'Big data' approaches for novel anti-cancer drug discovery.

Graeme Benstead-Hume1, Sarah K Wooller1, Frances M G Pearl1.   

Abstract

INTRODUCTION: The development of improved cancer therapies is frequently cited as an urgent unmet medical need. Recent advances in platform technologies and the increasing availability of biological 'big data' are providing an unparalleled opportunity to systematically identify the key genes and pathways involved in tumorigenesis. The discoveries made using these new technologies may lead to novel therapeutic interventions. Areas covered: The authors discuss the current approaches that use 'big data' to identify cancer drivers. These approaches include the analysis of genomic sequencing data, pathway data, multi-platform data, identifying genetic interactions such as synthetic lethality and using cell line data. They review how big data is being used to identify novel drug targets. The authors then provide an overview of the available data repositories and tools being used at the forefront of cancer drug discovery. Expert opinion: Targeted therapies based on the genomic events driving the tumour will eventually inform treatment protocols. However, using a tailored approach to treat all tumour patients may require developing a large repertoire of targeted drugs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28462602     DOI: 10.1080/17460441.2017.1319356

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  4 in total

Review 1.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

2.  Cancer cachexia: an orphan with a future.

Authors:  Mitja Lainscak; Giuseppe M C Rosano
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-02       Impact factor: 12.910

3.  MAEL contributes to gastric cancer progression by promoting ILKAP degradation.

Authors:  Xing Zhang; Yichong Ning; Yuzhong Xiao; Huaxin Duan; Guifang Qu; Xin Liu; Yan Du; Dejian Jiang; Jianlin Zhou
Journal:  Oncotarget       Date:  2017-12-06

4.  Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature.

Authors:  Yoosup Chang; Hyejin Park; Hyun-Jin Yang; Seungju Lee; Kwee-Yum Lee; Tae Soon Kim; Jongsun Jung; Jae-Min Shin
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.